ecrin-mdr-crcClinical2021colorectal cancerColorectal CancerInterventionalhttps://newmdr.ecrin.org/Study/2702727China2ECRIN MDRRecruitingfalseReal-world study of the efficacy and safety of bevacizumab for first-line and post-first-line treatment of advanced RAS mutated colorectal cancerInterventions: experimental group:chemotherapy combined with bevacizumab Primary outcome(s): Progression-Free Survival;Overall Survival Study Design: Sequential2021-02-152702727ChiCTR2100042553